Bristol Myers flashes a thumbs-up on pivotal push to expand Abecma's BCMA CAR-T market
Bristol Myers Squibb and their partners at 2seventy bio have flagged a top-line win for KarMMa-3, one in a series of pivotal studies looking to move Abecma (idecabtagene vicleucel) up the line to earlier-stage multiple myeloma patients.
We won’t get the hard data until later in the year, but for now, the pharma giant and its biotech marketing sidekick want you to know that Abecma scored on statistical significance for third-line patients on the primary endpoint: superior progression-free survival compared to standard of care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
